MESO FY 2020 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$32M+92.3% YoY

Gross Profit

-$49M-153.4% margin

Operating Income

-$75M-232.8% margin

Net Income

-$78M-242.4% margin

EPS (Diluted)

$-1.50

Cash Flow

Operating Cash Flow

-$56M

Free Cash Flow

-$59M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$734M

Total Liabilities

$184M

Stockholders' Equity

$549M

Cash & Equivalents

$129M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$32M	$17M	+92.3%
Gross Profit	-$49M	-$58M	+15.6%
Operating Income	-$75M	-$80M	+6.6%
Net Income	-$78M	-$90M	+13.2%